Each week we highlight five things affecting the life sciences industry. Here’s the latest.
Iran-linked cyberattack disrupts U.S. medtech company operations
- NBC News reports that an Iran-linked hacker group has claimed responsibility for a cyberattack on a U.S. medtech company.
- Experts describe this to be the first significant instance of Iran’s hacking an American company since the start of the war.
UK launches regulatory pathway for space-based drug manufacturing
- The UK has introduced a new regulatory roadmap to enable pharmaceutical manufacturing in space, aiming to leverage microgravity to improve the formulation, stability and delivery of complex biologic drugs, according to the European Medical Journal.
- The initiative aligns multiple regulators and funding programs to support orbital drug production and create clear approval pathways for medicines developed in space, positioning the UK as a potential leader in this emerging field.
Biotech startups tap funding extensions to dodge full financing rounds
- Biotech startups are increasingly relying on funding extensions or insider-led top-ups, often from existing investors, to quickly add runway without going out for a full, repriced financing round in a weak capital market.
- According to Endpoints News, these extensions help companies avoid down rounds and valuation resets, but they also signal how difficult it remains to raise new outside capital, with many startups effectively buying time rather than securing long-term financing solutions.
FDA unveils new pilot bonus program for faster reviews
- The U.S. Food and Drug Administration unveiled a pilot bonus program that would financially reward agency reviewers for completing drug reviews faster, framing it as a way to recognize efficiency while still factoring in work quality and complexity, not just speed.
- The program is intended to help address significant staffing, morale and retention challenges at the FDA, but it has sparked internal and external concern about whether tying pay to faster reviews could risk perceived or real pressure on scientific rigor and patient safety, reports Endpoints News.
Resurgence in small molecules as orphan drugs
- Fierce Biotech reports small molecules now account for roughly 45% of the top 20 most valuable orphan drugs in development, outpacing biologics like monoclonal antibodies, as deeper disease biology insights, improved chemistry and data‑driven tools (including artificial intelligence) renew interest in the modality.
- Despite their resurgence in pipelines, small molecules still face regulatory and commercial risk in orphan indications, highlighted by high‑profile setbacks and the continued dominance of oncology—though dealmaking signals growing momentum in non‑oncology rare diseases.
For more insights in life sciences, check out RSM’s industry outlook.
